Showing 13 to 15 of 15 results


Europe's Shifting Drug Landscape: From Heroin Dominance to Multi-Substance Use
A shift in European drug trends sees heroin no longer the primary drug problem, though it remains a significant cause of overdose deaths; however, the rise of multiple substance use, increased trafficking, and related violence necessitates a reassessment of drug policies and treatments.
Europe's Shifting Drug Landscape: From Heroin Dominance to Multi-Substance Use
A shift in European drug trends sees heroin no longer the primary drug problem, though it remains a significant cause of overdose deaths; however, the rise of multiple substance use, increased trafficking, and related violence necessitates a reassessment of drug policies and treatments.
Progress
36% Bias Score


French Drug Market: Alarming Rise in Cocaine Purity and Potent Cannabis Products
A new OFDT report details the alarming increase in cocaine purity (44%), the emergence of high-THC cannabis products (up to 78% delta-9-THC causing severe intoxication), and the appearance of novel synthetic opioids and cannabinoids in France in 2023, based on 731 samples analyzed by the Sintes syst...
French Drug Market: Alarming Rise in Cocaine Purity and Potent Cannabis Products
A new OFDT report details the alarming increase in cocaine purity (44%), the emergence of high-THC cannabis products (up to 78% delta-9-THC causing severe intoxication), and the appearance of novel synthetic opioids and cannabinoids in France in 2023, based on 731 samples analyzed by the Sintes syst...
Progress
24% Bias Score

Sackler Family Agrees to $7.4 Billion Opioid Settlement
The Sackler family and Purdue Pharma agreed to a $7.4 billion settlement over opioid crisis lawsuits, with the Sacklers paying up to $6.5 billion and relinquishing company ownership, exceeding a previous, rejected deal.

Sackler Family Agrees to $7.4 Billion Opioid Settlement
The Sackler family and Purdue Pharma agreed to a $7.4 billion settlement over opioid crisis lawsuits, with the Sacklers paying up to $6.5 billion and relinquishing company ownership, exceeding a previous, rejected deal.
Progress
40% Bias Score
Showing 13 to 15 of 15 results